Roche Holding Ag Stock Price To Sales

RHHVF Stock  USD 279.58  3.08  1.09%   
Roche Holding AG fundamentals help investors to digest information that contributes to Roche Holding's financial success or failures. It also enables traders to predict the movement of Roche OTC Stock. The fundamental analysis module provides a way to measure Roche Holding's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Roche Holding otc stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Roche Holding AG OTC Stock Price To Sales Analysis

Roche Holding's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

 = 

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Roche Holding Price To Sales

    
  3.97 X  
Most of Roche Holding's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Roche Holding AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Competition

Based on the latest financial disclosure, Roche Holding AG has a Price To Sales of 3.9696 times. This is 81.45% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The price to sales for all United States stocks is 65.24% higher than that of the company.

Roche Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Roche Holding's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Roche Holding could also be used in its relative valuation, which is a method of valuing Roche Holding by comparing valuation metrics of similar companies.
Roche Holding is currently under evaluation in price to sales category among its peers.

Roche Fundamentals

About Roche Holding Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Roche Holding AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Roche Holding using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Roche Holding AG based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Roche OTC Stock

Roche Holding financial ratios help investors to determine whether Roche OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Roche with respect to the benefits of owning Roche Holding security.